Seres Therapeutics, Inc. (MCRB) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Seres Therapeutics reported revenue of $789,000. Net income was $5.7M (a 721.9% net margin), or $0.64 per diluted share. Operating margin was -11910.1%. Operating activities generated $1.1M of cash, leaving $865,000 of free cash flow. At fiscal year end, Seres Therapeutics held $138.2M in total assets against $94.0M in total liabilities, including $45.8M of cash and equivalents.
Open the full interactive Seres Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Seres Therapeutics Key Stats
| Share Price | $2.53 |
|---|---|
| Market Cap | $24.7M |
| P/E Ratio | 4.0 |
| 52-Week Range | $2.53 – $28.63 |
| Shares Outstanding | 9.7 million (basic, 2026 Q2) |
Seres Therapeutics Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $33.2M | $144.9M | $7.1M | $126.3M | $0 | $789,000 |
| Operating Income | -$88.1M | -$64.5M | -$246.5M | -$108.0M | -$121.3M | -$94.0M |
| Pre-Tax Income | -$89.1M | -$65.6M | -$250.2M | -$113.7M | $136,000 | $5.7M |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$89.1M | -$65.6M | -$250.2M | -$113.7M | $136,000 | $5.7M |
| Diluted EPS | -$22.40 | -$14.40 | -$46.20 | -$17.80 | — | $0.64 |
Seres Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $351,000 | $438,000 | $358,000 | $736,000 |
| Net Income | $8.2M | -$15.3M | -$19.9M | $4.6M |
| Diluted EPS | $0.94 | -$1.73 | -$2.08 | $0.47 |
Seres Therapeutics Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $116.0M | $180.0M | $163.0M | $128.0M | $30.8M | $45.8M |
| Current Assets | $268.8M | $303.6M | $194.8M | $175.4M | $38.7M | $49.4M |
| Total Assets | $342.9M | $354.9M | $348.8M | $358.6M | $139.8M | $138.2M |
| Current Liabilities | $46.4M | $82.3M | $85.6M | $98.7M | $41.2M | $19.3M |
| Total Long-Term Debt | $25.0M | $24.1M | $50.0M | $110.0M | — | — |
| Total Liabilities | $168.2M | $223.4M | $338.0M | $403.5M | $126.0M | $94.0M |
| Shareholders' Equity | $174.8M | $131.5M | $10.8M | -$44.9M | $13.8M | $44.2M |
Seres Therapeutics Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$93.6M | $6.7M | -$228.8M | -$117.4M | -$148.6M | $1.1M |
| Cash From Investing | -$158.9M | $64.1M | $82.4M | $10.6M | $142.3M | -$42,000 |
| Cash From Financing | $303.4M | $1.2M | $129.6M | $71.7M | -$90.4M | $13.9M |
| Free Cash Flow | -$94.2M | -$2.9M | -$238.6M | -$125.3M | -$149.0M | $865,000 |
Figures from Seres Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Seres Therapeutics financials page for every line item.
Seres Therapeutics Company Profile
| Ticker | MCRB |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Cambridge, Massachusetts |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001609809 |
Frequently Asked Questions
What was Seres Therapeutics' revenue in fiscal 2025?
Seres Therapeutics (MCRB) reported revenue of $789,000 for fiscal 2025.
What is Seres Therapeutics' annual revenue history?
Seres Therapeutics' annual revenue by fiscal year: 2020: $33.2M; 2021: $144.9M; 2022: $7.1M; 2023: $126.3M; 2024: $0; 2025: $789,000.
What was Seres Therapeutics' net income in fiscal 2025?
Seres Therapeutics reported net income of $5.7M for fiscal 2025.
What was Seres Therapeutics' earnings per share (EPS) in fiscal 2025?
Seres Therapeutics' diluted EPS was $0.64 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Seres Therapeutics generate in fiscal 2025?
Seres Therapeutics generated $865,000 of free cash flow in fiscal 2025.
What was Seres Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Seres Therapeutics reported revenue of $736,000.
How many shares of Seres Therapeutics are outstanding?
Seres Therapeutics reported a weighted average of 9.7 million basic shares outstanding in 2026 Q2.
What is Seres Therapeutics' market cap?
Based on its latest closing price, Seres Therapeutics (MCRB) has a market capitalization of about $24.7M.
When does Seres Therapeutics' fiscal year end?
Seres Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Seres Therapeutics headquartered?
Seres Therapeutics lists its business address in Cambridge, Massachusetts in its SEC filings.